This consistency in the day is crucial because Semaglutide has a long half-life, meaning it stays in your system and maintains its therapeutic effects for approximately seven days
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
The reactions people describe most often are anxiety, heart palpitations, and headaches
Participants were randomized to placebo or one of five retatrutide dose groups (1 mg, 4 mg escalating, 4 mg fixed, 8 mg escalating, 12 mg escalating)
18 Most of these studies do not report HF diagnostic criteria or mention HF therapy, and only one trial reported on left ventricular ejection fraction (LVEF) at baseline